PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31600901-6	2019	Our data shows that the Dox treatment significantly increased expression of inflammasome markers (TLR4 and NLRP3), pyroptotic markers (caspase-1, IL1-beta, and IL-18), cell signaling proteins (MyD88, p-P38, and p-JNK), pro-inflammatory M1 macrophages, and TNF-alpha cytokine.	Doxorubicin	24-27	interleukin 18	Mus musculus	160-165	
28926719-6	2018	The results show significant increase in the expression of caspase-1, IL-1beta, and IL-18 following treatment with Dox, which was inhibited by ES-exos but not mouse embryonic fibroblast exosomes.	Doxorubicin	115-118	interleukin 18	Mus musculus	84-89	
34474337-5	2021	Mechanismly, MCC950 had the potential to inhibit DOX-induced the cleavage of NLRP3, ASC, Caspase-1, IL-18, IL-1beta and GSDMD in vivo.	Doxorubicin	49-52	interleukin 18	Mus musculus	100-105	
25801352-8	2015	To establish the significance of IL-18 in EoE pathogenesis, we examined DOX-inducible rtTA-CC10-IL-18 bitransgenic mice that induce IL-18 protein expression in the oesophagus.	Doxorubicin	72-75	interleukin 18	Mus musculus	96-101	
25801352-8	2015	To establish the significance of IL-18 in EoE pathogenesis, we examined DOX-inducible rtTA-CC10-IL-18 bitransgenic mice that induce IL-18 protein expression in the oesophagus.	Doxorubicin	72-75	interleukin 18	Mus musculus	96-101